White Matter Lesions Defined By Diffusion Tensor Imaging In Older Adults

White Matter Lesions Defined By Diffusion Tensor Imaging In Older Adults Average ratng: 9,2/10 234reviews

An error occurred while setting your user cookie. Please set your. browser to accept cookies to continue. NEJM. org uses cookies to improve performance by remembering your. ID when you navigate from page to page. This cookie stores just a.

ID; no other information is captured. Accepting the NEJM cookie is.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative: Comparison of neuroimaging modalities for the.

Multiple Sclerosis Differential Diagnoses. Polman CH, Reingold SC, Banwell B, et al.

Diagnostic criteria for multiple sclerosis: 2. Mc. Donald criteria. Ann Neurol. 2. 01. Feb. 6. 9(2): 2. 92- 3. Medline]. [Full Text]. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Ann Neurol. 1. 98. Mar. 1. 3(3): 2. 27- 3.

Medline]. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1. 99.

Apr. 4. 6(4): 9. 07- 1. Medline]. Mc. Donald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2. 00.

White Matter Lesions Defined By Diffusion Tensor Imaging In Older Adults

Jul. 5. 0(1): 1. 21- 7. Medline]. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae- Grant A. Evidence- based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2. 01. Jan 1. 8. 7. 6(3): 2.

Medline]. [Full Text]. Sanford M, Lyseng- Williamson KA. Subcutaneous recombinant interferon- ß- 1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2. 01. 1 Oct 1. Medline]. Betaseron [package insert]. Montville, NJ: Bayer Healthcare Pharmaceuticals Inc. Special Meeting Minutes.

NERVOUS SYSTEM DISEASE Ed Friedlander, M.D., Pathologist scalpel_blade@yahoo.com No texting or chat messages, please. Ordinary e-mails are welcome. Brain research in the last forty-years has culminated in earth shaking changes as to how we understand and describe the brain and brain injury. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults.

May 2. 01. 0. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon ß- 1a for relapsing- remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double- blind study. Lancet Neurol. 2.

Jul. 1. 3(7): 6. 57- 6. Medline]. Copaxone [package insert] [package insert]. North Wales, PA: Teva Pharmaceuticals USA. February 2. 00. 9.

Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev. Oct 5. CD0. 07. 62. Medline]. Tysabri [package insert]. South San Francisco, CA: Biogen Idec Inc. Novantrone [package insert].

Rockland, MA: Serono, Inc. May 2. 01. 2. Gilenya [package insert]. East Hanover, NJ: Novartis. September 2. 01. 0.

Aubagio (teriflunomide) [package insert]. Cambridge, MA: Genentech Corp. September, 2. 01. Available at [Full Text].

Jeffrey S. FDA approves third oral agent for MS. March 2. 7, 2. 01. Medscape Medical News. Available at http: //www. Accessed: April 2, 2. US Food and Drug Administration.

FDA approves new multiple sclerosis treatment: Tecfidera. March 2. 7, 2. 01. Available at http: //www. News. Events/Newsroom/Press. Watery Diarrhoea In Adults. Announcements/ucm.

Accessed: April 2, 2. Gold R, Kappos L, Arnold DL, Bar- Or A, Giovannoni G, Selmaj K, et al. Placebo- controlled phase 3 study of oral BG- 1. N Engl J Med. 2. 01. Sep 2. 0. 3. 67(1.

Medline]. [Full Text]. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al.

Placebo- controlled phase 3 study of oral BG- 1. N Engl J Med. 2. 01. Sep 2. 0. 3. 67(1. Medline]. [Full Text].

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first- line treatment for patients with relapsing- remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2. 01. 2 Nov 2.

Medline]. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease- modifying therapy: a randomised controlled phase 3 trial. Lancet. 2. 01. 2 Nov 2. Medline]. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab more effective than interferon ß- 1a at 5- year follow- up of CAMMS2.

Neurology. 2. 01. Apr 3. 7. 8(1. 4): 1. Medline]. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus Interferon Beta- 1a in Relapsing Multiple Sclerosis.

N Engl J Med. 2. 01. Oct 8. 3. 73 (1. 5): 1. Medline]. [Full Text]. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high- yield process in relapsing- remitting multiple sclerosis (SELECT): a randomised, double- blind, placebo- controlled trial. Lancet. 2. 01. 3 Jun 2. Medline]. Jeffrey S.

FDA Approves Interferon Autoinjector for MS. Available at http: //www. Accessed: February 2. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7- 1 (CD8.

B7- 2 (CD8. 6), and interleukin 1. J Exp Med. 1. 99. Dec 1. 1. 82(6): 1. Medline]. [Full Text]. Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in multiple sclerosis patients.

J Neurosci Res. 2. Jul 1. 8. 1(1): 4. Medline]. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th. 17 cells in human disease.

Immunol Rev. 2. 00. Jun. 2. 23: 8. 7- 1. Medline]. [Full Text]. Minagar A, Jy W, Jimenez JJ, et al.

Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2. 00. May 2. 2. 5. 6(1. Medline]. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR.

Ig. G marker of optic- spinal multiple sclerosis binds to the aquaporin- 4 water channel. J Exp Med. 2. 00.